Notably, CD11cAb-IFNA169D was able to bind with specificity to cDC1s in spleen and tumor resulting in 100% CD11c RO in the spleen and ~70% CD11c RO in the tumor following a single injection with just 10 μg (0.5 mg/kg) (Figure 8B). This evidence concerns the gene ITGAX and neoplasm.